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In vitro synergy testing using levoﬂoxacin (LVX) plus piperacillin/tazobactam (TZP) was performed by Etest and time-kill assay
(TKA)for31uniqueﬂuoroquinolone-resistantPseudomonasaeruginosaisolates.TheEtestmethodshowedsynergyfor9/31(29%)
of isolates, while TKA showed synergy with 14/31 (45%) of isolates. When comparing the Etest method and TKA, concordant
results for synergy, antagonism, and indiﬀerence were obtained for 24/31 (77%) of the isolates tested.
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1.Introduction
Pseudomonas aeruginosa is a major nosocomial pathogen,
and eﬀective therapy represents a great challenge. P. aerug-
inosa strains are often resistant to antibacterial agents
from diﬀerent classes, including β-lactams, aminoglycosides,
and ﬂuoroquinolones; some strains are only susceptible to
polymyxins [1]. The mechanisms of resistance of P. aerug-
inosa are determined by both chromosomal and plasmid
genes encoding diﬀerent resistance enzymes (β-lactamases,
including extendedspectrumβ-lactamases,carbapenemases,
etc.); other mechanisms include decreased bacterial wall
permeability, target alterations, and active drug eﬄux
[2].
Commonly, treatment of P. aeruginosa involves a com-
bination of antibacterial agents. Levoﬂoxacin (LVX) plus
piperacillin/tazobactam (TZP) is an antipseudomonal reg-
imen used in many hospitals. The putative beneﬁts are
to increase eﬃcacy by achieving synergistic killing and
preventing the emergence of antibiotic resistance, but data
are sparse. A recent retrospective cohort study demonstrated
a reduction in 28-day all-cause mortality in less severely ill
patients (533 of 702 patients, (75.9%)) with monomicrobial
bacteremia due to aerobic gram-negative bacilli (including P.
aeruginosa) who received either a combination of a β-lactam
plus LVX or ciproﬂoxacin versus β-lactam monotherapy [3].
This supported an in vivo synergistic or additive eﬀect of the
β-lactam plus ﬂuoroquinolone combination.
Three methods to detect in vitro synergy have been
described:thetime-killassay(TKA),checkerboard,andEtest
method. Earlier invitrostudiesusing TKAand checkerboard
techniques suggested diﬀerent rates of synergy (17–83%) of
LVX plus TZP (4–6; H Jones and E Swiatlo, 41st Annual
Meeting Infectious Diseases Society of America, Abstr. 230,
2003) or piperacillin [4–6] against P. aeruginosa.T w oT K A
studies by Burgess et al. [7, 8] were similar with 12 P.
aeruginosa isolates and showed 67–83% synergy. However,
only 4/12 isolates were resistant to either LVX or TZP.
Another study—by Jones and Swiatlo [2003]—with the
same combination tested 100 P. aeruginosa isolates by the
checkerboard method, showing 17% synergy. Drago et al.
[9] performed the checkerboard and TKA methods against
resistant P. aeruginosa, showing synergy in 6/30 (20%) and
(75%) isolates, respectively. Studies by White et al. [10]
and Bonapace et al. [11] evaluated the use of Etest for
synergy testing by placing the Etest strips on the agar in
a cross formation, with a 90◦ angle at the intersection
between the scales at the respective MICs for the organism.
In the study by White et al. [10], the agreement between
their Etest method and TKA ranged 63–75% and agreement
betweenthecheckerboardmethodandTKAranged44–88%.
Correlationwasdependentonthebacterium(Escherichiacoli2 Interdisciplinary Perspectives on Infectious Diseases
ATCC35218, EnterobactercloacaeATCC23355, P. aeruginosa
ATCC 27853, and Staphylococcus aureus ATCC 29213) and
antibiotic tested (cefepime or ceftazidime in combination
with tobramycin or ciproﬂoxacin). Similarly, in the study
by Bonapace et al. [11], the agreement between Etest and
TKA ranged 42–97% and 30–67% for the checkerboard
methodandTKA,respectively.Thisstudyincluded10strains
of Acinetobacter baumannii, and antimicrobial combina-
tions evaluated consisted of trovaﬂoxacin or tobramycin in
combination with cefepime or piperacillin. Antagonism was
diﬃcult to detect with their method. Both studies concluded
that additional testing using an Etest method needed to be
performed.
Synergy testing methods are not standardized for repro-
ducibility and interpretation; therefore, it is extremely diﬃ-
culttocomparethesemethods’resultsfromdiﬀerentstudies.
In the TKA for synergy, drug concentrations are ﬁxed and
do not decrease over time, as they would in vivo. Also,
there are no standard concentrations at which antibiotics
are tested. The inoculum size and time frame of the TKA
add more variability to the test. The time parameter of 24
hours can limit or alter results of the experiment if regrowth
occurs with one or both antibiotics. Regrowth can be caused
by the use of a subinhibitory concentration of antibiotics.
Emergence of resistant subpopulations may account for the
regrowth, or regrowth may be due to bacteria that adhere to
the surface of the bottle and are subsequently released in the
medium. Another factor aﬀecting regrowth is inactivation
of the antibiotics in vitro. The TKA for synergy testing
measures bactericidal activity but is time-consuming and
labor-intensive.
In the checkerboard technique, serial dilutions of two
drugs are performed in tubes or microtiter wells using drug
concentrations equal to, above, and below the MICs of
the drugs being tested. The checkerboard method measures
inhibitory activity. Only if each microdilution well at the
MIC and greater is subcultured for growth would this
method predict bactericidal activity. Because TKA and
checkerboard measure diﬀerent activities, study results have
shown poor agreement [10–14]. There are limitations asso-
ciated with both methods. In the study by Cappelletty and
Rybak [13], methodologies for synergy testing of resistant P.
aeruginosa were compared, and problems were discussed.
The third method for determining synergy, the Etest
synergy method, is relatively new. The use of the Etest strip
for synergy has yet to be standardized but has the potential
to be a useful screening test for determining synergy. We
have further modiﬁed the Etest synergy method to use
a concentration equal to 1 × MIC for each drug [15].
An MIC-to-MIC placement of the strips seems to give a
more accurate diﬀusion of the two drugs and the eﬀects
(if any) that each drug has on the other in combination
against the organism. The technique is simple to use, time-
eﬃcient, and inexpensive. Because the checkerboard method
and TKA are laborious and time-consuming [16], they are
not performed in clinical laboratories. With no approved
standard method for in vitro synergy testing available, Etest
could be an alternative method for the study of the activities
of antimicrobial combinations.
With the recently published clinical study by Al-Hasan
et al. [3] showing in vivo synergy with the commonly used
antipseudomonalLVX/TZPcombination,wefeltthatadding
more in vitro synergy data, including 31 highly-resistant P.
aeruginosa strains, was indicated. The aim of this present
study was twofold: (1) to test for synergistic activity of LVX
and TZP against P. aeruginosa, including ﬂuoroquinolone-
resistantstrainsand(2)tocompareresultsfromtwodiﬀerent
synergy testing methods, TKA and Etest.
2.MaterialsandMethods
Thirty-one unique clinical, genetically distinct ﬂuoroquin-
olone-resistant P. aeruginosa isolates were collected from
October 1999 through June 2003 from ﬁve hospitals in the
New Orleans area. Fingerprinting of isolates was performed
by pulsed-ﬁeld gel electrophoresis, using criteria by Tenover
et al. [17], where a 0–3 band diﬀerence is interpreted
as indistinguishable. The isolates were cultured from the
lower respiratory tract (11), wound (9), urine (6), blood
(2), ear (1), catheter tip (1), and bone (1). All strains’
identiﬁcation and susceptibility testing were performed by
the Vitek System (bioM´ erieux Inc., Hazelwood, MO, USA).
The percent susceptible was amikacin (58%), ceftazidime
(29%), ceftriaxone (10%), gentamicin (16%), imipenem
(35%), TZP (39%), LVX (0%), ciproﬂoxacin (0%), and
tobramycin (74%). P. aeruginosa ATCC 27853 was used for
quality control. Mueller-Hinton broth (Becton-Dickinson
Microbiology Systems, Sparks, MD, USA) was prepared
in the laboratory. Mueller-Hinton II agar (MHA) plates
(Becton-Dickinson) were used for the Etest MIC determina-
tion and the Etest synergy method. Trypticase soy agar with
5% sheep blood plates (Becton-Dickinson) were used for
the colony counts in TKA. Standard laboratory powders—
LVX (Johnson and Johnson Pharmaceutical Research and
Development, Springhouse, PA, USA) and TZP (Wyeth
Research, Pearl River, NY, USA)—and Etest strips (AB
Biodisk, Solna, Sweden) were used.
Etest MICs for LVX and TZP were determined in
triplicate following the manufacturer’s guidelines and the
mean used. The Etest concentration range (μg/mL) tested
was 0.002–32 for LVX and 0.016–256 for TZP. Clinical and
Laboratory Standards Institute (CLSI) interpretive standards
(μg/mL) for P. aeruginosa were applied: LVX ≤ 2i ss u s c e p t i -
ble, = 4 intermediate, ≥ 8 resistant; TZP ≤ 64 is susceptible
and ≥ 128 is resistant [18].
2.1. Synergy Testing
2.1.1. Etest Synergy Method. The Etest synergy method
[15] was performed in triplicate, the summation fractional
inhibitory concentration (

FIC) was calculated for each set
of MICs, and the mean

FIC was used for comparison
to the TKA results. The inoculum and streaked MHA
plates for each isolate were prepared the same as for Etest
MICs. LVX and TZP Etest strips were applied to diﬀerent
sections of an MHA plate. The agar was marked adjacent
to the previously determined MIC on each Etest strip. The
strips were removed after incubating for 1 hour at roomInterdisciplinary Perspectives on Infectious Diseases 3
Table 1: Etest MIC (μg/mL), Etest Synergy Method, and Time-Kill Assay.
P. aeruginosa
n = 31 LVX MIC TZP MIC Synergy Testing (LVX + TZP)
Etest TKA
Etest(a) Etest(a) ΣFIC(a) Log10change
(b)
1 > 32 > 256 2.0 I −1.4I
28 > 256 0.4 S −3S
33 2 > 256 0.4 S 0I
∗
4 > 32 > 256 2.0 I −2S
∗
5 > 32 4 1.2 I −0.7I
6 > 32 16 0.5 S −3.4S
7 > 32 4 1.0 I −2S
∗
8 > 32 > 64 2.0 I +1.3I
93 2 > 4 0.004 S −2.4S
10 > 32 > 40 . 8 I + 1 .4I
11 > 32 > 256 1.5 I +1.3I
12 > 32 > 256 2.0 I −1.5I
13 > 32 > 256 1.2 I −0.7I
14 > 32 > 256 2.0 I −0.4I
15 > 32 > 256 2.0 I −1I
16 > 32 > 256 0.2 S −2S
17 > 32 16 1.4 I −0.4I
18 > 32 > 256 2.0 I −0.6I
19 > 32 > 256 1.3 I −1.1I
20 > 32 > 256 2.0 I −3.2S
∗
21 > 32 32 0.9 I −4S
∗
22 > 32 > 256 2.0 I −0.1I
23 > 32 32 0.5 S −2S
24 > 32 16 1.1 I −0.4I
25 > 32 > 256 0.6 I −1.3I
26 > 32 32 0.8 I −3.8S
∗
27 > 32 > 256 0.5 S −2S
28 > 32 8 1.0 I −3.3S
∗
29 > 32 > 256 1.1 I −1.1I
30 > 32 > 256 0.3 S −2.1S
31 > 32 > 256 0.3 S −2.8S
∗Pseudomonas aeruginosa strains with discordant synergy results. (a)Performed in triplicate. (b)Values represent the log10 change in CFU/mL in the time-kill
assay after 24 hour exposure to the combination of levoﬂoxacin (LVX) and piperacillin/tazobactam (TZP) compared to the most active drug alone. Negative
values indicate a decrease in colony count; positive values indicate an increase in colony count. S: synergy; I: indiﬀerence.
temperature. Using an Etest applicator, a new LVX strip was
placed over the area of the previously removed TZP strip so
that the LVX MIC corresponded with the mark of the TZP
MIC. TZP strips were applied in reciprocate fashion. This
established a concentration ratio of 1 × MIC for each of
the two antimicrobials. The resulting combination ellipses
were read after approximately 20 hours of incubation at
35◦C. To evaluate the eﬀect of the combinations, the FIC
was calculated for each antibiotic in each combination, and
the mean

F I Cw a su s e df o rc o m p a r i s o nt oT K A .H i g ho ﬀ-
scale MICs were converted to the next twofold dilution. The
following formulas were used to calculate ΣFIC: (1) FIC of
LVX = MIC of LVX in combination/MIC of LVX alone; (2)
FIC of TZP = MIC of TZP in combination/MIC of TZP
alone; (3) ΣFIC = FIC of LVX + FIC of TZP. Synergy was
deﬁned as ΣFIC ≤ 0.5. Antagonism was deﬁned as ΣFIC > 4.
Interactions with ΣFIC > 0.5 but ≤ 4 were termed indiﬀerent
[16].
2.1.2. Time-Kill Assay. TKAs were performed according
to CLSI guidelines [19]. An approximately 105 CFU/mL
inoculum was veriﬁed after plating in duplicate using a spiral
plater and scanner (Spiral Biotech, Bethesda, MD, USA).
Each isolate was tested against LVX and TZP alone and in
combination at a concentration equal to the mean Etest
MIC. A concentration equal to the mean Etest MIC was used
so that TKA results could be compared directly with the
Etest synergy method (which uses 1 × MIC for each drug).4 Interdisciplinary Perspectives on Infectious Diseases
When the MIC for either drug was greater than the highest
concentration value on the strip, the highest concentration
on the strip was used in the TKA. Colony counts on all
isolates were performed at 0 hour and 24 hours. Performing
serial dilutions and plating with a spiral plater, which further
dilutes and plates the sample, helped reduce the possibility
of antibiotic carryover. The spiral plater/scanner was used to
a c c u r a t e l yd e t e c tb a c t e r i a lc o u n t sa sl o wa s2 0C F U / m L .
Synergy was deﬁned as a ≥ 2l o g 10 decrease in colony
count after 24 hours by the combination compared to
the most active single agent, and the number of surviving




active drug alone. Antagonism was deﬁned as a ≥ 2log 10
increase in colony count after 24 hours by the combination
compared to the most active drug alone [16]. TKA results,
which were discordant to the Etest synergy results, were
repeated and conﬁrmed the initial TKA ﬁndings.
3. Results andDiscussion
Etest MICs for the P. aeruginosa isolates were LVX 8-
>32μg/mL (all resistant) and TZP 4->256μg/mL (61%
resistant). Synergy was found in 9/31 (29%) of isolates
using Etest and 14/31 (45%) using TKA. Six isolates were
indiﬀerent by the Etest method (

FIC: 2, 1, 2, 0.9, 0.8, 1)
but synergistic with the TKA method (log10 change: −2, −2,
−3.2, −4, −3.8, −3.3). One isolate was synergistic with Etest
(

FIC = 0.4) but indiﬀerent with TKA (log10 change = 0).
There was good agreement for synergy between Etest (32%)
and TKA (37%) when both drugs were resistant. Agreement
was not as good between Etest and TKA (25% vs. 58%) when
TZP was susceptible Concordance between Etest and TKA
was high: 24/31 (77%) (see Table 1) However since there no
gold standard for synergy testing it is diﬃcult to establish
which method is more accurate. There was no evidence of
in vitro antagonism.
Atleastthree possible reasonsmay explain the discrepan-
cies in results between Etest and TKA. First, our isolates were
highly LVX (100%) and TZP (61%) resistant, with MICs
often exceeding the Etest strip detection limit; therefore, we
empirically used the next twofold dilution for ΣFIC calcu-
lation. This makes it diﬃcult to interpret the results and is
clearly a limitation of the Etest method. Second, the current
Etest ΣFIC criteria for synergy are simply imported from the
checkerboard methodology and may need adjustments for
Etest. Last, the TKA data were analyzed based on CFU/mL
changes comparing the eﬀect of the combination with the
eﬀect of the most potent drug, whereas Etest data were
analyzed with FIC indexes comparing concentrations of the
drugs alone and in combination.
Etest was able to detect slight hazes of growth and
resistant subpopulations. Because the MICs of both drugs
were read as bactericidal endpoints, these resistant colonies
were included when reading the endpoint for the Etest
MIC. Lorian showed that bacteria grown on a surface are
signiﬁcantly diﬀerent from bacteria grown in liquid medium
[20]. The diﬀerences include growth rate, adherence, and
susceptibility to antibacterial agents, as well as diﬀerences
in the biochemical constitutions of the bacteria themselves
and their metabolites. One major diﬀerence is in the
ultrastructure. Evidence indicates that bacteria in vivo grow
and produce disease on surfaces and not in body ﬂuids
[20–23]. The identical ultrastructures of bacteria found in
vivo and organisms grown in vitro on a surface support the
theorythatinvitroexperimentsaimingatduplicatinginvivo
conditions should be performed on solid media.
The present study, which included all LVX-resistant and
61% TZP-resistant P. aeruginosa strains, showed synergy by
Etest (29%) and TKA (45%) and conﬁrms previous in vitro
synergy data using β-lactam/ﬂuoroquinolone combinations.
Previous in vitro synergy studies showed 17–83% synergy,
depending on the method used.
4. Conclusion
Some in vitro synergy with LVX plus TZP could be
demonstrated with both TZP-susceptible and TZP-resistant
P. aeruginosa strains, and no antagonism was found. The
high concordance (77%) between Etest and TKA suggests
that the Etest method may be an alternative to time-kill
studies for in vitro synergy testing of P. aeruginosa with LVX
and TZP. Etest is simple to use, time-eﬃcient, inexpensive,
and reproducible and yielded results comparable to TKA. In
vitro synergy may or may not translate into in vivo synergy.
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